Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka


Background: The association between herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus (HIV) and the development of HSV vaccines have increased interest in the study of HSV epidemiology.

Objectives: To estimate the age and sex specific seroprevalence of HSV-1 and HSV-2 infections in selected populations in Brazil, Estonia, India, Morocco, and Sri Lanka.

Methods: Serum samples were collected from various populations including children, antenatal clinic attenders, blood donors, hospital inpatients, and HIV sentinel surveillance groups. STD clinic attenders were enrolled in Sri Lanka, male military personnel in Morocco. Sera were tested using a common algorithm by type specific HSV-1 and HSV-2 antibody assay.

Results: 13 986 samples were tested, 45.0% from adult females, 32.7% from adult males, and 22.3% from children. The prevalence of HSV-1 varied by site ranging from 78.5%–93.6% in adult males and from 75.5%–97.8% in adult females. In all countries HSV-1 seroprevalence increased significantly with age (p<0.001) in both men and women. The prevalence of HSV-2 infection varied between sites. Brazil had the highest age specific rates of infection for both men and women, followed by Sri Lanka for men and Estonia for women, the lowest rates being found in Estonia for men and India for women. In all countries, HSV-2 seroprevalence increased significantly with age (p<0.01) and adult females had higher rates of infection than adult males by age of infection.

Conclusions: HSV-1 and HSV-2 seroprevalence was consistently higher in women than men, particularly for HSV-2. Population based data on HSV-1 and HSV-2 will be useful for designing potential HSV-2 vaccination strategies and for focusing prevention efforts for HSV-1 and HSV-2 infection.
Samples were anonymised. Age and sex were the only data available on each sample.

**Laboratory methods**

A “minimum” testing algorithm was developed to avoid unnecessary testing of samples; the level of childhood infection with HSV-1 infection was determined in sera from 1–11 year olds. If the HSV-1 antibody prevalence was greater than 80% in these children, only a random sample of 20% of the adult (that is, age >11 years) sera were tested from that country. All sera from adults aged 12 years and older were tested for HSV-2 antibody. In practice, however, four of five laboratories tested all sera for antibodies to both HSV-1 and HSV-2, as this was logistically simpler to do.

**Validation and standardisation of laboratory methods**

All primary testing of sera from the main serum banks and reference panels for HSV-1 and HSV-2 was undertaken using the indirect HSV-1 (gG1) and HSV-2 (gG2) antibody assays (HerpesSelect, Focus Technologies, CA, USA). These assays had previously been shown to be both sensitive and specific, and FDA approved. Assay kits obtained from one manufacturing batch were obtained in bulk and distributed to the sites by the Central Public Health Laboratory (CPHL), London, UK.

To validate the testing performed in each participating laboratory, CPHL distributed a panel of sera previously tested with the reference HSV type specific blocking assays. The panel consisted of 88 sera which included a range of HSV-1 and HSV-2 negative, equivocal and positive specimens, and was tested blind.

All participating centres tested the reference panel twice, before and after testing the study sera, with the Focus ELISA kits for HSV-1 and HSV-2. Qualitative and quantitative results of reference panel testing were returned to CPHL. All laboratories achieved greater than 90% sensitivity compared to consensus. For the HSV-1 reference panel, all laboratories except Morocco achieved specificity and positive predictive values of greater than 90% compared to the consensus results. For Morocco, these values were 88% and 90% respectively. For the HSV-2 reference panel, all laboratories achieved specificity and positive predictive values of 97% or greater, compared to the consensus results.

A subset of sera was retested at CPHL, using the in-house type specific binding ELISA assay. Retested sera included all equivocal sera (for HSV-1 or HSV-2) and a random sample of double (HSV-1 and HSV-2) negative sera.

**Statistical analysis**

Data were double entered into Epi-Info at each site and then sent to the department of STD, University College London (UCL) for analysis. Data analysis was undertaken using SPSS version 10.0. For the purposes of analysis, a category of “low risk” group was devised. This comprised hospital inpatients (Sri Lanka), blood donors (Estonia, Brazil, India, Sri Lanka), and participants recruited during a national HIV sentinel surveillance sampling frame (Morocco). Analyses were stratified according to country, sex, and age (for the adult groups).

Differences in proportions were tested using the $\chi^2$ test. Logistic regression was used to examine differences in age and sex specific prevalence by country, using Morocco, as the reference. The odds of HSV-2 infection among individuals with and without HSV-1 was calculated in adults aged 20 years and over who had been tested for both HSV-1 and HSV-2. The analysis was restricted to those aged 20 and over (89.9% of sample) on the basis that the majority of these would be sexually active and hence have the potential to have been exposed to each virus.

**Ethical issues**

The ethics review boards of the respective institutions approved the study. The samples were tested in an anonymised fashion.

### Table 1: Number of serum samples tested for antibodies to HSV-1 and HSV-2

<table>
<thead>
<tr>
<th>Low risk groups</th>
<th>Children</th>
<th>Antenatal</th>
<th>Females*</th>
<th>Males*</th>
<th>Military</th>
<th>STD clinic attenders†</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rio de Janeiro, Brazil</td>
<td>697</td>
<td>399</td>
<td>84</td>
<td>398</td>
<td>–</td>
<td>–</td>
<td>1578</td>
</tr>
<tr>
<td>Tartu, Estonia</td>
<td>1016</td>
<td>794</td>
<td>574</td>
<td>462</td>
<td>–</td>
<td>–</td>
<td>2846</td>
</tr>
<tr>
<td>Vellore, India</td>
<td>361</td>
<td>990</td>
<td>48</td>
<td>394</td>
<td>–</td>
<td>–</td>
<td>1793</td>
</tr>
<tr>
<td>Morocco</td>
<td>637</td>
<td>1663</td>
<td>–</td>
<td>621</td>
<td>679</td>
<td>–</td>
<td>3600</td>
</tr>
<tr>
<td>Ragama, Sri Lanka</td>
<td>433</td>
<td>757</td>
<td>684</td>
<td>1619</td>
<td>– 676</td>
<td>–</td>
<td>4169</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>3144</td>
<td>4603</td>
<td>1390</td>
<td>3494</td>
<td>679 676</td>
<td>–</td>
<td>13986</td>
</tr>
</tbody>
</table>

*Blood donors (Brazil, Estonia, India, and Sri Lanka), HIV sentinel surveillance participants (Morocco), adult hospital inpatients (Sri Lanka).

| 1400/676 (59.2%) of the Sri Lankan STD clinic attenders were men.

| All samples collected from Sri Lanka, India, and Moroccan military were collected prospectively. 85%, 24.7%, and 12.6% of Estonia, Moroccan civilians, and Brazil’s samples, respectively, were collected prospectively. The remaining samples were collected in 1998 (6.1%) and 1999 (17.7%), except for those collected on Brazilian children, which were all collected as part of a vaccine study in 1992.

<table>
<thead>
<tr>
<th>Brazil</th>
<th>Estonia</th>
<th>India</th>
<th>Morocco</th>
<th>Sri Lanka</th>
</tr>
</thead>
<tbody>
<tr>
<td>36</td>
<td>31.4</td>
<td>36</td>
<td>100</td>
<td>40.5</td>
</tr>
<tr>
<td>55.4</td>
<td>52.4</td>
<td>68.7</td>
<td>55.5</td>
<td>53.1</td>
</tr>
<tr>
<td>68.8</td>
<td>64.7</td>
<td>75.9</td>
<td>80.5</td>
<td>74</td>
</tr>
<tr>
<td>83.3</td>
<td>79.3</td>
<td>85.7</td>
<td>86.4</td>
<td>74.3</td>
</tr>
<tr>
<td>88.3</td>
<td>80.2</td>
<td>92.2</td>
<td>92.2</td>
<td>79.2</td>
</tr>
<tr>
<td>95.2</td>
<td>91</td>
<td>85.7</td>
<td>92.2</td>
<td>74.6</td>
</tr>
<tr>
<td>92.9</td>
<td>92.4</td>
<td>79.9</td>
<td>98.8</td>
<td>74.5</td>
</tr>
<tr>
<td>96</td>
<td>96.1</td>
<td>95.5</td>
<td>100</td>
<td>77.1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Brazil</th>
<th>Estonia</th>
<th>India</th>
<th>Morocco</th>
<th>Sri Lanka</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–1</td>
<td>36</td>
<td>31.4</td>
<td>36</td>
<td>100</td>
<td>40.5</td>
</tr>
<tr>
<td>2–5</td>
<td>55.4</td>
<td>52.4</td>
<td>68.7</td>
<td>55.5</td>
<td>53.1</td>
</tr>
<tr>
<td>6–10</td>
<td>68.8</td>
<td>64.7</td>
<td>75.9</td>
<td>80.5</td>
<td>74</td>
</tr>
<tr>
<td>11–15</td>
<td>83.3</td>
<td>79.3</td>
<td>85.7</td>
<td>86.4</td>
<td>74.3</td>
</tr>
<tr>
<td>16–20</td>
<td>88.3</td>
<td>80.2</td>
<td>92.2</td>
<td>92.2</td>
<td>79.2</td>
</tr>
<tr>
<td>21–35</td>
<td>95.2</td>
<td>91</td>
<td>85.7</td>
<td>92.2</td>
<td>74.6</td>
</tr>
<tr>
<td>36–45</td>
<td>92.9</td>
<td>92.4</td>
<td>79.9</td>
<td>98.8</td>
<td>74.5</td>
</tr>
<tr>
<td>45+</td>
<td>96</td>
<td>96.1</td>
<td>95.5</td>
<td>100</td>
<td>77.1</td>
</tr>
</tbody>
</table>

**Figure 1** HSV-1 seroprevalence [%] by age group and country, males and females combined.
The crude HSV-2 prevalences by country, sex, and population type are shown in Table 3 (see Table 2).

### Table 2: Odds of infection with HSV-1 and HSV-2 by country after adjusting for age (excluding STD clinic attenders from Sri Lanka)

<table>
<thead>
<tr>
<th>Country</th>
<th>HSV-1 +ve % (95% CI)</th>
<th>Adjusted odds ratios of HSV-1 (95% CI)</th>
<th>Adjusted odds ratios of HSV-2 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>29.3 (24.9 to 33.8)</td>
<td>42.9 (32.1 to 54.1)</td>
<td>25.9 (21.6 to 30.2)</td>
</tr>
<tr>
<td>Estonia</td>
<td>23.8 (20.8 to 26.8)</td>
<td>21.1 (17.7 to 24.4)</td>
<td>10.8 (8.0 to 13.7)</td>
</tr>
<tr>
<td>India</td>
<td>7.9 (6.3 to 9.7)</td>
<td>14.6 (6.1 to 27.8)</td>
<td>10.2 (7.2 to 13.1)</td>
</tr>
<tr>
<td>Morocco</td>
<td>12.9 (11.3 to 14.5)</td>
<td>9.2 (7.1 to 11.8)</td>
<td>6.5 (4.7 to 8.6)</td>
</tr>
<tr>
<td>Sri Lanka</td>
<td>8.3 (6.5 to 10.5)</td>
<td>21.2 (18.1 to 24.3)</td>
<td>49.3 (43.4 to 55.4)</td>
</tr>
</tbody>
</table>

*Estonia has similar HSV-1 seroprevalence to India (p=0.31), significantly lower HSV-1 prevalence than Brazil (p=0.005), and significantly higher HSV-1 prevalence than Sri Lanka (p<0.000) after adjusting for age.
*Brazil has significantly higher HSV-1 prevalence than Sri Lanka (p<0.000) after adjusting for age.
†Brazilian women had significantly higher prevalence than Sri Lankan (p<0.000) and similar prevalence to Sri Lankan.
‡Brazilian women had significantly higher prevalence than Sri Lankan (p<0.000) and Sri Lankan (p=0.49) women after adjusting for age.
††Brazilian men had significantly higher HSV-2 prevalence than Brazilian (p<0.000) and similar prevalence to Sri Lankan.
†§Indian women had significantly lower HSV-2 prevalence than Brazilian (p=0.1), and significantly higher HSV-1 prevalence than Sri Lanka (p<0.000) after adjusting for age.
‡‡Estonian women significantly lower HSV-2 prevalence than Brazilian (p<0.000) women and significantly higher HSV-2 prevalence than Indian (p<0.000).
†††Indian women had significantly lower HSV-2 prevalence than Sri Lankan (p=0.000) and similar prevalence to Sri Lankan.
‡‡‡Indian women had significantly lower HSV-2 prevalence than Brazilian (p<0.000) and similar prevalence to Sri Lankan.
††††Indian men had significantly lower HSV-2 prevalence than Brazilian (p<0.000) and similar prevalence to Sri Lankan.
‡‡‡‡Brazilians men had significantly higher prevalence than Sri Lankan (p<0.000) and similar prevalence to Sri Lankan.
†††††Brazilian men had significantly higher HSV-1 prevalence than Sri Lankan (p<0.000) and similar prevalence to Sri Lankan.
‡‡‡‡‡Brazilians men had significantly higher HSV-2 prevalence than Brazilian (p<0.000) and similar prevalence to Sri Lankan.

**RESULTS**

Overall, 13,986 samples were included in the study; 45% of samples (n=6269) were collected from women, 32.7% from men (n=4573), and 22.3% (n=3144) from children and adolescents (age 0–19 years). The majority (88%) were from people resident in urban areas. A detailed breakdown of the number of specimens tested from each country is given in Table 1.

### Epidemiology of HSV-1

The HSV-1 seroprevalence among male adults at different sites ranged from 78.5%–93.6% and among female adults from 75.9% to 97.8%. The age specific HSV-1 seroprevalences are shown in Figure 1. At all sites HSV-1 seroprevalence increased significantly with age (t test for equality of mean ages among people who HSV-2 positive and HSV-2 negative, p<0.001 for all countries).

There were significant differences in the age specific prevalence between countries, with all countries having significantly lower risk of infection than Morocco (Table 2). The age at which 25%, 50%, and 75% of the population became HSV-1 positive and who are HSV-1 negative, p<0.01 for all countries).

### Epidemiology of HSV-2

The crude HSV-2 prevalences by country, sex, and population type are shown in Table 3 (see STI website for details).

The age specific seroprevalences are shown in Figure 2 (for women) and Figure 3 (for men). In all countries HSV-2 seroprevalence increased significantly with age (t test for equality of mean ages among people who HSV-2 positive and HSV-2 negative, p<0.01 for all countries).

The age and sex adjusted odds ratios of HSV-2 relative to Morocco for low risk men and women are shown by country in Table 2.

Overall, the odds of HSV-2 infection among adults (aged 20 years and over) with HSV-1 infection compared to those without was 1.32 (95% CI 1.12 to 1.55).

In Brazil, Estonia, India, and Sri Lanka all the samples collected from children were tested for antibodies to HSV-2 (n=2510). The HSV-2 seroprevalence was 0.5% (95% CI: 0.1 to 0.9) in Estonia, 2.2% (95% CI: 0.7 to 3.7) in India, 2.4% (95% CI: 1.0 to 3.8) in Brazil, and 4.8% (95% CI: 2.8 to 6.8) in Sri Lanka. Fifteen of the 21 seropositive sera taken from 433 children in Sri Lanka were retested using the reference assay. Only 3/10 gave positive results in both assays.

### DISCUSSION

This study describes the age and sex specific seroprevalence of HSV-1 and HSV-2 in selected populations in Brazil, Estonia, India, Morocco, and Sri Lanka. These data confirm that the
majority of infections with HSV-1 occur during childhood, although the age of acquisition varies between countries. By contrast, very few children were found to be infected with HSV-2. The low rate of confirmation of children’s HSV-2 positive sera from Sri Lanka suggests that a proportion of these sera represent false positive results, as might be anticipated in a very low prevalence population with the test characteristics described. The proportion of adults infected with HSV-2 increased with age in all communities and, overall, women had higher rates of infection than men, although this was not the case in India. Again the rate of HSV-2 infection varied between countries with Brazil having the highest age specific rates of infection for both men and women.

While the pattern and distribution of HSV-2 infection is becoming increasingly understood, relatively few studies to date have examined the seroprevalence of HSV-1. These data confirm that universal infection with HSV-1 early in childhood is not the norm. Infection during adolescence appears to be common in both Brazil and Estonia. Later acquisition of HSV-1 may be altering the epidemiology and presentation of genital herpes in these countries. A recent serological survey of over 5000 samples collected as part of the UK PHLS serosurveillance programme showed that the rate of infection among 10–14 year olds had dropped from 34% in 1986–7 to 24% in 1994–5, which has been accompanied by an increase in the proportion of first episode genital herpes cases due to HSV-1. Understanding the seroepidemiology of HSV-1 in children is critical to defining HSV vaccine strategies, if a vaccine that only worked in people who are HSV naive is to be further investigated. Such a vaccine would have no practical use in countries with high rates of HSV-1 in early childhood as we have shown occurs in India, Morocco, and Sri Lanka and, possibly, Brazil and Estonia as well.

Previous studies have shown conflicting evidence concerning the protective effect of HSV-1 for HSV-2, with some studies suggesting it has a protective effect and others finding no evidence of this. In this study, we did not find that having HSV-1 infection reduced the likelihood of HSV-2. Individuals aged 20 years and over with HSV-1 antibody were significantly more likely to be infected with HSV-2 than those without.

In developing countries, the major public health importance of HSV-2 relates to its potential role in facilitating HIV transmission. However, limited data on HSV-2 prevalence are available from many parts of the world, especially eastern Europe, Asia, and South America. A recent workshop conducted under the auspices of UNAIDS and WHO reviewed existing knowledge concerning the epidemiology and control of HSV-2, and its interaction with HIV. Experts concluded that estimates of HSV and HIV infections were needed by sex and age group in order to explore possible differences in the effect of HSV-2 on HIV acquisition between males and females, and to determine target groups for interventions. Although data on sexual behaviour were not collected in this study, the high HSV-2 seroprevalence found in Brazilian and Estonian women may indicate a high risk for STD and HIV exposure in those populations. Rates of bacterial STDs are also high in eastern Europe.

These data were generated from various hospital populations and convenience samples within the five countries studied. Although not strictly representative of the general population of those countries they do provide useful insight into the extent of infection and how it varies with age and sex and as such would provide a useful benchmark for sample size estimates for more definitive epidemiological or intervention studies.

ACKNOWLEDGEMENTS

The authors wish to thank all those who contributed to the collection of samples in the sites.

The study was supported by a grant from GlaxoSmithKline (GSK).

CONTRIBUTORS

FC, PM, NJR, and DB designed the study and contributed to analysis; RF was the overall study coordinator and carried the statistical analysis, with FC; DB and RG coordinated the laboratory aspects; SA, AU, SR, REA, MR, NPS were the centres’ coordinators; FC and PM wrote the first draft of the paper to which all authors contributed.

Conflict of interest: NJR is an employee of GSK. FC has acted as a consultant for GSK. FC, RF, and DB have all accepted funding from GSK to attend meetings.
Authors' affiliations

F M Cowan, R S French, Department of Sexually Transmitted Diseases, Royal Free and University College Medical School, University College London, London, UK
P Mayaud, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
R Gopal, D W Brown, Enteric, Respiratory and Neurological Virus Laboratory, Central Public Health Laboratories, Colindale, London, UK
N J Robinson, Worldwide Epidemiology, GlaxoSmithKline R&D, Greenford, Middlesex, UK
S Artimos de Oliveira, University Federal Fluminense, Niteroi, Brazil
T Faillace, Polyclinica Comunitaria Santa Rosa, Niteroi, Brazil
A Uusküla, University of Tartu, Tartu, Estonia
M Nygård-Kibur, Institute of Experimental and Clinical Medicine, Tallinn, Estonia
S Ramalingam, G Sridharan, Christian Medical College Hospital, Vellore, India
R El Aouad, Institut National d’Hygiene de la Sante, Rabat, Morocco
K Alami, Programme National de Lutte contre la SIDA/MST, Ministere de la Sante Publique, Rabat, Morocco
M Rbai, Hospital d’Instruction Militaire Mohammed V, Rabat, Morocco
N P Sunil-Chandra, University of Kelaniya, Ragama, Sri Lanka

REFERENCES


STI eLetters

Letters on the following papers have been published recently as rapid responses on the STI website. To read these letters visit www.stijournal.com and click on “Read eLetters”:

Diagnosis and treatment of presumed STIs at Mexican pharmacies: survey results from a random sample of Mexico City pharmacy attendants A N Turner, C Ellertson, S Thomas, et al. Sex Transm Infect 2003;79:224–8


If you would like to post an electronic response to these or any other articles published in the journal, please go to the web site, access the article in which you are interested, and click on “eLetters: Submit a response to this article” in the box in the top right hand corner.